MEF2D functions as a tumor suppressor in breast cancer
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1109388 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR28968057_1.fastq.gz | Fastqsanger.gz | |||
| SRR28968057_2.fastq.gz | Fastqsanger.gz | |||
| SRR28968058_1.fastq.gz | Fastqsanger.gz | |||
| SRR28968058_2.fastq.gz | Fastqsanger.gz | |||
| SRR28968059_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 10 |
Similar Datasets
Project description:The myocyte enhancer factor 2 (MEF2) gene family plays fundamental roles in the genetic programs that control cell differentiation, morphogenesis, proliferation, and survival in a wide range of cell types. The molecular programs they regulate and their role in tumor development and progression remain incompletely understood. The present study evaluated whether the MEF2D transcription factor functions as a tumor suppressor in breast cancer. We found knockout of the MEF2D gene in mouse mammary epithelial cells resulted in phenotypic changes characteristic of neoplastic transformation, including: enhanced cell proliferation, loss of contact inhibition, and anchorage-independent growth in soft agar, as well as capacity for tumor development in mice. Through RNAseq analysis, we found knockout of MEF2D induced the epithelial-to-mesenchymal transition (EMT) and activated several oncogenic signaling pathways. In summary, our study indicates that MEF2D may be a putative tumor suppressor, acting through selective gene regulatory programs that have clinical and therapeutic significance in breast cancer.
2025-05-08 | GSE267037 | GEO
Project description:In this study, we identify leucyl-tRNA synthetase (LARS) as a breast tumor suppressor. To identify the mechanism underlying LARS-mediated breast tumor suppression, we conducted TMT-proteomics in PyMT mouse tumors with monoallelic genetic deletion of LARS in the mammary tumor compartment. The analyses implicate LARS as a regulator of leucine-rich protein translation resulting in downregulation of candidate leucine-rich tumor suppressor genes.
2022-01-10 | PXD026609 | Pride
Project description:Expression of the tumor suppressor protein BRCA1 is frequently lost in breast cancer patients, and the loss of its expression is associated with disruption of various critical functions in cells and cancer development. In the present study, we demonstrated that microarray analysis of cells with tumor suppressor candidate 4 (TUSC4) knockdown indicated critical changes such as cell cycle, cell death pathways and a global impact to cancer development. More importantly, we observed a clear cluster pattern of TUSC4-knockdown gene profiles with established homologous recombination (HR) repair defect signature. Additionally, TUSC4 protein can physically interact with E3 ligase Herc2 and prevents BRCA1 degradation via ubiquitination pathway. Knockdown of TUSC4 expression enhanced BRCA1 polyubiquitination, leading to BRCA1 protein degradation and a marked reduction in HR repair efficiency. Notably, ectopic expression of TUSC4 effectively suppressed the proliferation, invasion, and colony formation of breast cancer cells in vitro and tumorigenesis in vivo. Furthermore, knockdown of TUSC4 expression transformed normal mammary epithelial cells and enhanced the sensitivity of U2OS cells to the treatment of poly(ADP-ribose) polymerase inhibitors. Therefore, TUSC4 may act as a bona fide tumor suppressor by regulating BRCA1 protein stability and function in breast cancer. Two groups of samples are included: 1.U2OS-shcontrol 2.U2OS-shTUSC4 knockdown. Gene expression profiles of U2OS-shTUSC4 cells were compared to that of parental U2OS-shcontrol cells.
2014-08-21 | E-GEOD-60535 | biostudies-arrayexpress
Project description:The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of breast cancer cases (60-80%). We find that c-Myb high expression in human breast tumors correlates with the luminal/ER+ phenotype and a good prognosis. RNAi knock-down of endogenous c-Myb levels in the MCF7 luminal breast tumor cell line increases tumorigenesis both in vitro and in vivo, suggesting a tumor suppressor role in luminal breast cancer. We created a mammary-derived c-Myb expression signature and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated with a mammary stem/progenitor lineage gene signature. These data describe, for the first time, a tumor suppressor role for the c-Myb proto-oncogene in breast cancer that has implications for understanding luminal tumorigenesis and for guiding treatment. refXsample
2010-10-15 | E-GEOD-21371 | biostudies-arrayexpress
Project description:Expression of the tumor suppressor protein BRCA1 is frequently lost in breast cancer patients, and the loss of its expression is associated with disruption of various critical functions in cells and cancer development. In the present study, we demonstrated that microarray analysis of cells with tumor suppressor candidate 4 (TUSC4) knockdown indicated critical changes such as cell cycle, cell death pathways and a global impact to cancer development. More importantly, we observed a clear cluster pattern of TUSC4-knockdown gene profiles with established homologous recombination (HR) repair defect signature. Additionally, TUSC4 protein can physically interact with E3 ligase Herc2 and prevents BRCA1 degradation via ubiquitination pathway. Knockdown of TUSC4 expression enhanced BRCA1 polyubiquitination, leading to BRCA1 protein degradation and a marked reduction in HR repair efficiency. Notably, ectopic expression of TUSC4 effectively suppressed the proliferation, invasion, and colony formation of breast cancer cells in vitro and tumorigenesis in vivo. Furthermore, knockdown of TUSC4 expression transformed normal mammary epithelial cells and enhanced the sensitivity of U2OS cells to the treatment of poly(ADP-ribose) polymerase inhibitors. Therefore, TUSC4 may act as a bona fide tumor suppressor by regulating BRCA1 protein stability and function in breast cancer.
2014-08-21 | GSE60535 | GEO
Project description:Identification of circRBM39 as a tumor suppressor in breast cancer
| PRJNA1224764 | ENA
Project description:BRCA1 inactivation is a hallmark of familial breast cancer, often encountered in aggressive triple negative breast cancers. BRCA1 is a tumor suppressor with known functions in DNA repair, transcription regulation, cell cycle control, and apoptosis. In the present study, we demonstrate that BRCA1 is also a translational regulator. Based on the combination of RNA-binding protein immunoprecipitation and microarray analysis, as well as polysome profiling, we identified a subset of mRNAs translationally regulated by BRCA1 and coding for proteins whose functions play major role in cancer. We found that the level of these key proteins is similarly controlled in human mammary tumors according to their BRCA1-status. Therefore, our results propose translational control as a novel molecular mechanism with clinical relevance through which BRCA1 is a tumor suppressor.
2020-05-21 | GSE119886 | GEO
Project description:BACKGROUND: The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of breast cancer cases (60-80%). METHODOLOGY/PRINCIPAL FINDINGS: We find that c-Myb high expression in human breast tumors correlates with the luminal/ER+ phenotype and a good prognosis. Stable RNAi knock-down of endogenous c-Myb in the MCF7 luminal breast tumor cell line increased tumorigenesis both in vitro and in vivo, suggesting a possible tumor suppressor role in luminal breast cancer. We created a mammary-derived c-Myb expression signature, comprised of both direct and indirect c-Myb target genes, and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated with a mammary stem/progenitor lineage gene signature. CONCLUSIONS/SIGNIFICANCE: These data describe, for the first time, a possible tumor suppressor role for the c-Myb proto-oncogene in breast cancer that has implications for the understanding of luminal tumorigenesis and for guiding treatment.
2010-10-15 | GSE21371 | GEO
Project description:The IER3 (Immediate Early Response 3) gene exhibits a multifaceted role in cancer biology, acting as both a tumor suppressor and an oncogene depending on the specific cancer type. This duality underscores the complexity of molecular pathways. Despite its significance, there is a dearth of studies dedicated to elucidating the exact mechanisms underlying IER3's involvement in cancer development. Recently, we identified that IER3 functions as an oncogene in cervix, breast, and lung cancer cell lines. In this study, we demonstrate for the first time that IER3 acts as a tumor suppressor in Neuroblastoma.
2025-03-13 | GSE279085 | GEO
Project description:The IER3 (Immediate Early Response 3) gene exhibits a multifaceted role in cancer biology, acting as both a tumor suppressor and an oncogene depending on the specific cancer type. This duality underscores the complexity of molecular pathways. Despite its significance, there is a dearth of studies dedicated to elucidating the exact mechanisms underlying IER3's involvement in cancer development. Recently, we identified that IER3 functions as an oncogene in cervix, breast, and lung cancer cell lines. In this study, we demonstrate for the first time that IER3 acts as a tumor suppressor in Neuroblastoma.
2025-03-13 | GSE279084 | GEO